The feasibility of utilizing plasma MiRNA107 and BACE1 messenger RNA gene expression for clinical diagnosis of amnestic mild cognitive impairment

Journal of Clinical Psychiatry

Volumn 76, Issue 2, 2015, Pages 135-141

  Wang, Tao ^a,b   Chen, Kewei ^c,d,e,f,g   Li, Huafang ^a   Dong, Shuhui ^a,b   Su, Ning ^a,b   Liu, Yuanyuan ^a,b   Cheng, Yan ^a,b   Dai, Jing ^a,b   Yang, Cece ^a,b   Xiao, Shifu ^a,b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Alzheimer's Disease and Related Disorders Center   (China)

^c SHANGHAI JIAO TONG UNIVERSITY   (China)

^d BANNER ALZHEIMER S INSTITUTE   (United States)

^e UNIVERSITY OF ARIZONA   (United States)

^f ARIZONA ALZHEIMER S CONSORTIUM   (United States)

^g ARIZONA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; BETA SECRETASE 1; MICRORNA 107; ASPARTIC PROTEINASE; BACE1 PROTEIN, HUMAN; GENETIC MARKER; MESSENGER RNA; MICRORNA; MIRN107 MICRORNA, HUMAN; SECRETASE;

AGED; ALZHEIMER DISEASE; ARTICLE; BACE1 GENE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE CLASSIFICATION; DSM-IV; FEASIBILITY STUDY; FEMALE; GENE EXPRESSION; HEALTH CARE ORGANIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; MIRNA 107 GENE; NATIONAL INSTITUTE OF NEUROLOGIC AND COMMUNICATIVE DISORDERS ASSOCIATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; REAL TIME POLYMERASE CHAIN REACTION; RNA GENE; SENSITIVITY AND SPECIFICITY; AMNESIA; BLOOD; CHINA; GENETIC MARKER; GENETICS; NEUROPSYCHOLOGICAL TEST; REFERENCE VALUE;

AGED; ALZHEIMER DISEASE; AMNESIA; AMYLOID PRECURSOR PROTEIN SECRETASES; APOLIPOPROTEINS E; ASPARTIC ACID ENDOPEPTIDASES; CHINA; FEASIBILITY STUDIES; FEMALE; GENE EXPRESSION; GENETIC MARKERS; HUMANS; MALE; MICRORNAS; MILD COGNITIVE IMPAIRMENT; NEUROPSYCHOLOGICAL TESTS; REFERENCE VALUES; RNA, MESSENGER;

EID: 84928414547     PISSN: 01606689     EISSN: 15552101     Source Type: Journal    
DOI: 10.4088/JCP.13m08812     Document Type: Article

References (37)

1. De Strooper B. Proteases and proteolysis in Alzheimer disease: A multifactorial view on the disease process. Physiol Rev. 2010;90(2):465-494. doi:10.152/physrev.023.209 PubMed
2. Dislich B, Lichtenthaler SF. Membrane-bound aspartyl protease BACE1: molecular and functional properties in Alzheimer's disease and beyond. Front Physiol. 2012;3:8. doi:10.389/fphys.2012.08 PubMed
3. Bettens K, Brouwers N, Engelborghs S, et al. APP and BACE1 miRNA genetic variability has no major role in risk for Alzheimer disease. Hum Mutat. 2009;30(8):1207-1213. doi:10.102/humu.21027 PubMed
4. Sathya M, Premkumar P, Karthick C, et al. BACE1 in Alzheimer's disease. Clin Chim Acta. 2012;414:171-178. doi:10.1016/j.ca.2012.08.013 PubMed
5. Hébert SS, Sergeant N, Buée L. MicroRNAs and the regulation of tau metabolism. Int J Alzheimers Dis. 2012;2012:406561. PubMed
6. Hébert SS, Papadopoulou AS, Smith P, et al. Genetic ablation of Dicer in adult forebrain neurons results in abnormal tau hyperphosphorylation and neurodegeneration. Hum Mol Genet. 2010;19(20):3959-3969. doi:10.1093/hmg/dq31 PubMed
7. Cogswell JP, Ward J, Taylor IA, et al. Identification of miRNA changes in Alzheimer's disease brain and CSF yields putative biomarkers and insights into disease pathways. J Alzheimers Dis. 2008;14(1):27-41. PubMed
8. Wang WX, Rajeev BW, Stromberg AJ, et al. The expression of microRNA miR-107 decreases early in Alzheimer's disease and may accelerate disease progression through regulation of beta-site amyloid precursor proteincleaving enzyme 1. J Neurosci. 2008;28(5):1213-1223. doi:10.1523/JNEUROSCI.5065-07.208 PubMed
9. Wang WX, Huang Q, Hu Y, et al. Patterns of microRNA expression in normal and early Alzheimer's disease human temporal cortex: white matter versus gray matter. Acta Neuropathol. 2011;121(2):193-205. doi:10.107/s0401-010-0756-0 PubMed
10. Wang WX, Wilfred BR, Madathil SK, et al. miR-107 regulates granulin/ progranulin with implications for traumatic brain injury and neurodegenerative disease. Am J Pathol. 2010;177(1):334-345. doi:10.2353/ajpath.2010.091202 PubMed
11. Müller M, Kuiperij HB, Claassen JA, et al. MicroRNAs in Alzheimer's disease: differential expression in hippocampus and cell-free cerebrospinal fluid. Neurobiol Aging. 2014;35(1):152-158. doi:10.1016/j.neurobiolaging.2013.07.05 PubMed
12. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34(7):939-944. doi:10.1212/WNL.34.7.939 PubMed
13. Petersen RC, Doody R, Kurz A, et al. Current concepts in mild cognitive impairment. Arch Neurol. 2001;58(12):1985-1992. doi:10.101/archneur.58.12.1985 PubMed
14. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189-198. doi:10.1016/02-3956(75)9026-6 PubMed
15. Katzman R, Zhang MY, Ouang-Ya-Qu, et al. A Chinese version of the Mini-Mental State Examination; impact of illiteracy in a Shanghai dementia survey. J Clin Epidemiol. 1988;41(10):971-978. doi:10.1016/0895-4356(8)9034-0 PubMed
16. Hachinski VC, Iliff LD, Zilhka E, et al. Cerebral blood flow in dementia. Arch Neurol. 1975;32(9):632-637. doi:10.101/archneur.1975.0490510809 PubMed
17. Schafer KA, Tractenberg RE, Sano M, et al; Alzheimer's Disease Cooperative Study. Reliability of monitoring the clinical dementia rating in multicenter clinical trials. Alzheimer Dis Assoc Disord. 2004;18(4):219-222. PubMed
18. Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA: A brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695-699. doi:10.1/j.1532-5415.205.5321.x PubMed
19. Stone CP, Girdner J, Albrecht R. An alternate form of the Wechsler Memory Scale. J Psychol. 1946;22(2):199-206. doi:10.1080/023980.1946.917307 PubMed
20. Mungas D. Differential clinical sensitivity of specific parameters of the Rey Auditory-Verbal Learning Test. J Consult Clin Psychol. 1983;51(6):848-855. doi:10.1037/02-06X.51.6.848 PubMed
21. Bayles KA, Tomoeda CK, Trosset MW. Naming and categorical knowledge in Alzheimer's disease: The process of semantic memory deterioration. Brain Lang. 1990;39(4):498-510. doi:10.1016/093-934X(90)90158-D PubMed
22. Sunderland T, Hill JL, Mellow AM, et al. Clock drawing in Alzheimer's disease: A novel measure of dementia severity. J Am Geriatr Soc. 1989;37(8):725-729. PubMed
23. Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3(1):32-35. doi:10.102/1097-0142(1950)3:1<32:AID-CNCR282030106>3.0.CO;2-3 PubMed
24. Coulson DT, Beyer N, Quinn JG, et al. BACE1 mRNA expression in Alzheimer's disease postmortem brain tissue. J Alzheimers Dis. 2010;22(4):1111-1122. PubMed
25. Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol. 2007;8(2):101-112. doi:10.1038/nrm2101 PubMed
26. Stockley JH, O'Neill C. Understanding BACE1: essential protease for amyloid-β production in Alzheimer's disease. Cell Mol Life Sci. 2008;65(20):3265-3289. doi:10.107/s018-08-8271-3 PubMed
27. Hussain I, Powell D, Howlett DR, et al. Identification of a novel aspartic protease (Asp 2) as beta-secretase. Mol Cell Neurosci. 1999;14(6):419-427. doi:10.106/mcne.19.081 PubMed
28. Sinha S, Anderson JP, Barbour R, et al. Purification and cloning of amyloid precursor protein beta-secretase from human brain. Nature. 1999;402(6761):537-540. doi:10.1038/9014 PubMed
29. Vassar R, Bennett BD, Babu-Khan S, et al. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science. 1999;286(5440):735-741. doi:10.126/science.286.540.735 PubMed
30. Yan R, Bienkowski MJ, Shuck ME, et al. Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity. Nature. 1999;402(6761):533-537. doi:10.1038/90107 PubMed
31. Lin X, Koelsch G, Wu S, et al. Human aspartic protease memapsin 2 cleaves the beta-secretase site of beta-amyloid precursor protein. Proc Natl Acad Sci U S A. 2000;97(4):1456-1460. doi:10.1073/pnas.97.4.1456 PubMed
32. Nelson PT, Wang WX. MiR-107 is reduced in Alzheimer's disease brain neocortex: validation study. J Alzheimers Dis. 2010;21(1):75-79. PubMed
33. Smith P, Al Hashimi A, Girard J, et al. In vivo regulation of amyloid precursor protein neuronal splicing by microRNAs. J Neurochem. 2011;116(2):240-247. doi:10.1/j.1471-4159.2010.07097.x PubMed
34. Yao J, Hennessey T, Flynt A, et al. MicroRNA-related cofilin abnormality in Alzheimer's disease. PLoS ONE. 2010;5(12):e15546. doi:10.1371/journal.pone.01546 PubMed
35. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):263-269. doi:10.1016/j.jalz.201.03.05 PubMed
36. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):270-279. doi:10.1016/j.jalz.201.03.08 PubMed
37. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):280-292.